Xanthohumol Isoprostane Pilot Study

Xanthohumol, at the dose of 5 mg. per day, produced an average reductionin oxidative stress as measured by isoprostanes of 36% in 3-weeks.

A pilot study was conducted with a proprietary formulation of xanthohumol in 8 subjectswith varying isoprostane levels. The principle isoprostane measured was 8-iso-prostaglandin F2 alpha, also known as IPF2-alpha-III normalized to creatinine. Urinesamples were collected and analyzed by LC/MS by an independent laboratory. Thehighest baseline was 1.69 g/g creatinine and the lowest was 0.18 g/g creatinine. Thesubjects were from 43 to 69 years in age, and there were 6 females and 2 males. Somesubjects were on various drugs such as cholesterol lowering or blood pressuremedication. The study was conducted by an independent third party research organizationunder an IRB, and with all appropriate record keeping. The medical history of eachsubject was documented, and each subject was instructed to keep a diary related tocompliance with instructions for when to take the product. Each subject took a dose of 5mg. of xanthohumol once a day in the evening, and recorded the time in their diary. Thebottles were weighed at the beginning and end of the study to monitor consumption. Theduration of the study was 3 weeks, and there were no adverse events recorded. Theaverage baseline isoprostane level was 0.57, and the average at the three-week time pointwas 0.36, or a drop of 36%. A double blind placebo controlled study in a larger numberof subjects will commence in the near future.

% Reduction of Isoprostane From Baseline

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1

IPF

2-a

lph

a-I

II

Baseline 3 Weeks